Mesoblast has reported that the commercial launch of Ryoncil (remestemcel-L-rknd), its FDA-approved mesenchymal stromal cell (MSC) product, was a focal point at recent global healthcare conferences in New York. According to the company, the product is the first FDA-approved MSC therapy, approved for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged two months and older.
The company said that Ryoncil’s first quarter launch performance was strong, with initial product sales in the paediatric SR-aGvHD population, and highlighted efforts to onboard additional treatment sites and expand product usage. Mesoblast claims plans are underway to extend Ryoncil’s use into adult SR-aGvHD and inflammatory bowel disease (IBD).
Mesoblast additionally shared updates on its second-generation product, Rexlemestrocel-L, including key Phase III development milestones. The company stated that it has established commercial partnerships in Japan, Europe and China, and that its intellectual property portfolio—which includes over 1,000 granted patents or applications—is expected to provide protection through at least 2041 in major markets.
The company also emphasized its manufacturing capabilities for producing off-the-shelf, cryopreserved cell therapies at industrial scale, designed to meet defined pharmaceutical release criteria and enable wider availability to patients.
